Pelthos Therapeutics
Pelthos Therapeutics is a biopharmaceutical company commercializing ZELSUVMI, the first FDA-approved at-home treatment for molluscum contagiosum, a common viral skin infection primarily affecting children. The product generated $7.1 million in net revenue in its first quarter of commercial operations, with 2,716 units prescribed by 1,169 unique prescribers. The company is also expanding its dermatology portfolio with XEPI, an FDA-approved topical treatment for impetigo.
- Healthcare Technology
- Drug Discovery & Therapeutics
- Biotechnology
Funding
Raised to date
$68.9MRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
across 3 rounds
$18M · Convertible Note
Announced Nov 2025
Disclosed cumulative: $68.9M
Founders
Founder details are not available yet.
Product
Problem
Molluscum contagiosum is a common, contagious skin infection that primarily affects children below the age of 14, with a US prevalence of 5.1%–11.5% in that age group. Despite its frequency, patients face limited treatment options, leaving a significant unmet burden for families and healthcare providers.
Solution
Pelthos Therapeutics is focused on commercializing innovative therapeutic products to help patients with unmet treatment burdens, with an initial emphasis on molluscum contagiosum. The company has launched ZELSUVMI, the first FDA-approved at-home treatment for this condition, which represents a significant shift in the treatment paradigm by enabling home-based care. The company is also expanding its portfolio with XEPI, a novel FDA-approved topical treatment for impetigo, a bacterial skin infection that primarily affects children. By targeting well-defined patient populations with clear clinical needs, Pelthos seeks to improve outcomes and reduce the burden of these infections on children and their caregivers.
Target Audience
Primary customers are pediatric patients affected by molluscum contagiosum and impetigo, along with their families, as well as pediatricians, dermatologists, and healthcare providers seeking effective treatment options for these common skin infections.
Features
- ZELSUVMI is the first FDA-approved at-home treatment for molluscum contagiosum, enabling treatment outside clinical settings
- Commercial launch generated $7.1 million in net revenue in the first quarter, with 2,716 units prescribed by 1,169 unique prescribers
- XEPI is a complementary FDA-approved topical treatment for impetigo, addressing antibiotic-resistant skin infections caused by staph and strep, affecting approximately 3 million people in the U.S. annually
- Portfolio targets pediatric dermatology conditions with high prevalence and clear unmet treatment needs
- Commercial infrastructure leverages existing sales relationships to cross-sell complementary products to the same target market